Vaccine News and Research

Latest Vaccine News and Research

African vaccine maker plans to increase production capacity sevenfold by 2013

Biovac Institute, a South African vaccine maker, said Monday that it is working with other major pharmaceutical firms to increase its annual capacity sevenfold to 35 million doses by 2013, Reuters reports.

28 Jan 2010

WHO addresses handling of H1N1 at Council of Europe meeting

During a Council of Europe meeting on Tuesday to address the WHO's handling of the H1N1 virus, the WHO said it had not "fallen under the sway of drugs firms and exaggerated the dangers of the H1N1 flu virus, but said it might have handled the crisis better," Reuters reports.

27 Jan 2010

Juvaris BioTherapeutics completes second close on its Series B equity financing

Juvaris BioTherapeutics, Inc., a biotechnology company developing adjuvanted vaccines for infectious diseases, announced that it has completed a second close on its Series B equity financing of up to $25 million. The additional equity investment came from an undisclosed strategic corporate investor who joins SV Life Sciences and Kleiner Perkins Caufield & Byers in the round.

27 Jan 2010

NIST researchers determine best practices for storing and monitoring refrigerated vaccines

Every year, billions of dollars worth of vaccines are shipped to thousands of medical providers across the country, and every year doctors must dispose of tens of millions of dollars worth of those vaccines because they became too warm or too cold while in storage.

27 Jan 2010

MBL generates human monoclonal antibodies against pandemic A type influenza virus

Medical & Biological Laboratories Co., Ltd. (MBL), with the collaboration of Osaka University, has successfully generated several fully human monoclonal antibodies against pandemic A (H1N1 and H3N2) type influenza virus by utilizing blood samples from volunteers who were inoculated with influenza vaccine.

27 Jan 2010

Researchers renew hope that effective vaccine could be developed against Salmonella infection

Research from Malawi, Birmingham and Liverpool has renewed hope that an effective vaccine could be developed against nontyphoidal strains of Salmonella. The work, funded by the Wellcome Trust and GlaxoSmithKline, suggests that the body's immune system could be primed to tackle even the most resilient of strains.

27 Jan 2010

Geron collaborates to explore hESC-based product for Alzheimer’s disease

Geron Corporation today announced that it has entered into a collaboration jointly funded by Geron and a University of California Discovery Research and Training Grant to investigate the therapeutic potential of its human embryonic stem cell (hESC)-based product, GRNOPC1, for Alzheimer’s disease. The company is currently developing GRNOPC1 for the potential treatment of spinal cord injury.

27 Jan 2010

Study: PROSTVAC-VF vaccine effective in treating patients with metastatic prostate cancer

In a newly published clinical trial, patients with metastatic prostate cancer who received a vaccine of harmless poxviruses engineered to spur an immune system attack on prostate tumor cells lived substantially longer than patients who received a placebo vaccine, report researchers at Dana-Farber Cancer Institute and affiliated organizations.

27 Jan 2010

Gates annual letter addresses importance of innovation for global health, agriculture

In his second annual letter, Bill Gates reflects on the Bill & Melinda Gates Foundation's work and the importance innovation will play in overcoming some of the world's greatest challenges, including in global health and agriculture, the Associated Press reports. "Gates says the foundation currently is backing 30 areas of innovation including online learning, teacher improvement, malaria vaccine development, HIV prevention, and genetically modified seeds," according to the news service (Gordon Blankinship, 1/25).

27 Jan 2010

UCF researcher develops first dual vaccine to fight malaria and cholera

A University of Central Florida biomedical researcher has developed what promises to be the first low-cost dual vaccine against malaria and cholera.

27 Jan 2010

Dr. Shinya Yamanaka to receive the 2010 March of Dimes Prize in Developmental Biology

The scientist who reprogrammed adult cells into embryonic-like stem cells has been chosen to receive the 2010 March of Dimes Prize in Developmental Biology.

27 Jan 2010

Health care providers play a critical role in H1N1 vaccinations

Results from the latest C.S. Mott Children's Hospital National Poll on Children's Health indicate health care providers play a critical role in influencing parents and patients to vaccinate their children and themselves against H1N1 flu.

27 Jan 2010

WHO rejects accusations it mishandled H1N1, updates worldwide stats

WHO spokesperson Gregory Hartl on Monday rejected accusations that the organization miscategorized H1N1 (swine flu) as a pandemic, calling such accusations "irresponsible," the Associated Press/Washington Post reports. "WHO also dismissed claims it colluded with drug companies to bring economic benefit to the industry by playing up the danger of the new H1N1 [swine flu] influenza strain," the news service writes.

27 Jan 2010

Texas to invest $4.5 mn in cancer research at UT Health Science Center

Texas plans to invest $3 billion in cancer research over the next 10 years and six scientists at The University of Texas Health Science Center at Houston are among the first to receive grants.The researchers, whose grants total $4.5 million, are working to protect girls from cervical cancer, to interrupt tumor growth at the molecular level and to develop a new approach for the treatment of colon cancer, among other cutting-edge projects.

27 Jan 2010

Dynavax Technologies to present data on its SD-101 Phase 1b trial for chronic HCV infection

Dynavax Technologies Corporation announced today data from two studies that differentiate SD-101 from standard-of-care as well as emerging treatments for chronic HCV infection. The findings of a Phase 1b clinical trial and an in vitro study of SD-101's mechanism of action show that the second-generation TLR9 agonist is well tolerated and safe and induces both IFN-lambda and IFN-alpha at concentrations producing antiviral activity. The data will be presented at the 45th Annual Meeting of the European Association for the Study of the Liver in Vienna, Austria in April 2010.

27 Jan 2010

Institute of Medicine urges healthcare providers to take steps to battle hepatitis B and C

The Institute of Medicine, a branch of the US National Academy of Sciences, is urging healthcare providers to take steps to battle liver-damaging hepatitis B and C, which are often overlooked viruses.

25 Jan 2010

Research paves way for future vaccine against gastric adenocarcinoma

Despite a strong response from our immune defence, the body is unable to rid itself of the bacterium Helicobacter pylori. One reason for this is that this bacterium encourages elements of the immune response to remain in tissue, activating the wrong immune cells. Research results that pave the way for a future vaccine are now being published by the Sahlgrenska Academy at the University of Gothenburg, Sweden.

25 Jan 2010

Bill Gates' annual letter highlights innovations aimed at combating disease, hunger and poverty

Bill Gates, co-chair of the Bill & Melinda Gates Foundation, today released his second annual letter -- a personal appraisal of the foundation's efforts to date and how innovation impacts priorities of the foundation.

25 Jan 2010

Erbitux improves survival of mCRC patients with KRAS wild-type tumors

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that Erbitux® (cetuximab) provided an improvement in overall survival (OS) when added to the standard 1st-line FOLFIRI chemotherapy regimen for metastatic colorectal cancer (mCRC) patients with KRAS wild-type tumors in the CRYSTAL study.

24 Jan 2010

Vaccination for children: Pros and cons

ProCon.org, a nonpartisan 501(c)3 nonprofit public charity dedicated to promoting critical thinking, created the new website http://vaccines.procon.org to explore the core question "Should any vaccines be required for children?"

23 Jan 2010

Vaccine News and Research

Latest Vaccine News and Research

African vaccine maker plans to increase production capacity sevenfold by 2013

WHO addresses handling of H1N1 at Council of Europe meeting

Juvaris BioTherapeutics completes second close on its Series B equity financing

NIST researchers determine best practices for storing and monitoring refrigerated vaccines

MBL generates human monoclonal antibodies against pandemic A type influenza virus

Researchers renew hope that effective vaccine could be developed against Salmonella infection

Geron collaborates to explore hESC-based product for Alzheimer’s disease

Study: PROSTVAC-VF vaccine effective in treating patients with metastatic prostate cancer

Gates annual letter addresses importance of innovation for global health, agriculture

UCF researcher develops first dual vaccine to fight malaria and cholera

Dr. Shinya Yamanaka to receive the 2010 March of Dimes Prize in Developmental Biology

Health care providers play a critical role in H1N1 vaccinations

WHO rejects accusations it mishandled H1N1, updates worldwide stats

Texas to invest $4.5 mn in cancer research at UT Health Science Center

Dynavax Technologies to present data on its SD-101 Phase 1b trial for chronic HCV infection

Institute of Medicine urges healthcare providers to take steps to battle hepatitis B and C

Research paves way for future vaccine against gastric adenocarcinoma

Bill Gates' annual letter highlights innovations aimed at combating disease, hunger and poverty

Erbitux improves survival of mCRC patients with KRAS wild-type tumors

Vaccination for children: Pros and cons

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Vaccine News and Research

Latest Vaccine News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in